"I love Seques"

2022-10-25 22:11:58

Toggle navigation About Answering your key questions What we do Our Team Get In Touch WE ARE THE FIRST HEALTHCARE COMMUNICATIONS AGENCY TO SPECIALIZE IN CELL AND GENE THERAPIES We combine expertise in cell and gene therapies with a global agency platform and extensive experience in healthcare communications We have been working exclusively with pharmaceutical and biotechnology companies developing and commercializing cell and gene therapies for over 5 years We are experienced in supporting companies with products in early-phase clinical development, as well as those commercializing cell and gene therapies for the first time Answering your key questions Communicate highly complex science Questions our clients ask Strategy, insights and influence Questions our clients ask Build and facilitate collaborations Questions our clients ask Design and digital innovation Questions our clients ask Integrated programme design Questions our clients ask What we do We have worked with multiple pharmaceutical and biotechnology companies, ranging from small start-ups to global organizationsWe have experience in working across >35 rare diseases, including 11 cell and gene therapies We use a range of tactics to extend the reach of data and engage multiple audiences Advisory boards Clinical trial education Congresses, symposia, and standalone meetings eLearning materials Internal training programmes Market access Mechanism of action videos and other science education Patient education materials Programme planning and tactical execution Publications Scientific messaging and communication platforms Stakeholder mapping and profiling Strategy and commercialization support Our Team Seques® is part of AMICULUM®, an independent family of 11 specialist branded agencies with over 350 medical communications professionals in 13 worldwide locations.Our team hold academic qualifications in genetics and many have practical experience of gene editing technologies.We collaborate with the wider AMICULUM family to provide clients with the optimal team size, expertise and skills tailored for their project. Get In Touch Find us on LinkedIn Patricia Jones [email protected] +44(0)7825536076 Jenny Szkolar [email protected] +44(0)7584571759 © 2022 SEQUES. All Rights Reserved Seques is a trading division of AMICULUM Consulting LimitedRegistered in England 8476405; registered office address: The Boathouse, Clarence Mill, Bollington, SK10 5JZ, UKView our cookie and privacy notice. Brighton Dundee London Manchester Close × Communicate highly complex science What is the best way to explain CRISPR-Cas9 gene editing to patients?Could you help us to prepare our cell therapy scientific narrative? × Strategy, insights and influence How can we keep patients and investigators updated and motivated throughout a 15-year trial?Could you design and deliver a workshop to identify educational gaps for each of our target audiences?Can you help us to identify which communication channel will have the most impact and resonate best for our content and/or target audiences? × Build and facilitate collaborations How do we identify our key stakeholders in cell and gene therapy?Could you help us to build a long-term steering committee, building trust and transparency, to support our clinical trial programme? × Design and digital innovation What can you suggest to make our virtual symposium stand out from the crowd?Could you support us in developing a 'one-stop shop' digital tool to support our MSL communications? × Integrated programme design We are launching an mRNA COVID-19 vaccine. Please could you help us to develop an integrated tactical programme for medical affairs? × Advisory boards Contact us to request a case study on advisory boards for a rare respiratory disease × Clinical trial education Contact us to request a case study on the development of leaflets, guidebooks and consent forms for a clinical trial of a gene-editing therapy × Congresses, symposia, and standalone meetings Contact us to request a case study on scientific engagement (symposia and standalone meetings) in a rare respiratory disease × eLearning materials Contact us to request a case study on app-based training for field conversations about a rare respiratory disease × Internal training programmes Contact us to request a case study on internal training for an mRNA-based vaccine for SARS-CoV-2 × Market access Contact us to request a case study on mapping the reimbursement landscape for a rare paediatric indication across Europe × Mechanism of action videos and other science education Contact us to request a case study on mechanism of action videos for lung and gastrointestinal cancers × Patient education materials Contact us to request a case study on patient materials for a gene therapy trial in a rare disease × Programme planning and tactical execution Contact us to request a case study on coordination of cross-functional tactical planning for a CAR-T cell therapy × Publications Contact us to request a case study on strategic publication planning and delivery for a cell therapy × Scientific messaging and communication platforms Contact us to request a case study on a scientific communication platform for a CAR-T cell therapy × Stakeholder mapping and profiling Contact us to request a case study on stakeholder mapping in rare haematological cancers × Strategy and commercialization support Contact us to request a case study on pre-launch planning for companies commercializing their first cell and gene therapy